Tech Company Financing Transactions
Dicerna Pharmaceuticals Funding Round
On 6/30/2010, Dicerna Pharmaceuticals raised $5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
6/30/2010
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
33 Hayden Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Dicerna (NASDAQ: DRNA) is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Fambrough
Chief Financial Officer
Jack Green
Chief Medical Officer
Ralf Rosskamp
Chief Scientific Officer
Bob Brown
Vice President
Jennifer Lockridge
VP - Bus. Development
James Weissman
VP - Operations
David Miller
Browse more venture capital transactions:
Prev: 6/30/2010: Achieve CCA venture capital transaction
Next: 6/30/2010: Blue Ash Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs